Astellas Beats Rivals To Japan HIF-PHI Market As Roxadustat Launched
Astellas becomes first to market in Japan in new class of oral anemia drugs, beating multiple rivals in a sector set to see strong growth but also fierce competition.
You may also be interested in...
Japan Nods Include Global Firsts For Duvroq, Vafseo And First Local Biosimilar Humira
Japan’s regulators have approved a large batch of new products, including a novel antibody from Chugai, two world-first nods for the country’s second HIF-PH inhibitors and an asthma therapy, and the first Humira biosimilar in Japan – as well as five drugs from Novartis.
Clear Path For AstraZeneca’s Roxadustat After Reassuring Safety Data
Strong results in non-dialysis patients are a particular boost for AZ and its partner, Fibrogen.
Vadadustat Emerges As Japan HIF-PHI Contender With First Filing Globally
Competition intensifies in novel anemia therapy space in Japan with first filing globally for Akebia/Mitsubishi Tanabe’s contender vadadustat, which could see its first launch worldwide in the country.